This Company Publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics--along with the development of microarray devices to measure analytes in the blood--has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts.
Table of Contents :
1. Overview 14 1.1 Statement of Report 14 1.2 About This Report 15 1.3 Scope of the Report 15 1.4 Objectives 17 1.5 Methodology 17 1.6 Executive Summary 19
2. Introduction to Molecular Diagnostics for Infectious Disease Testing 26 2.1 Molecular Diagnostics Testing and Opportunities in the Infectious Disease Sector 26 2.2 The Infectious Disease Problem 30 2.3 Impact of the Human Genome Project on Molecular Diagnostics 34 2.4 Opportunities for Molecular and Clinical Diagnostics 34 2.4.1 Companion Diagnostics 36 2.5 Development of Molecular Diagnostics Testing Markets 36 2.6 Target-based Gene Amplification 38 2.6.1 Polymerase Chain Reaction (PCR) 38 2.6.2 Real-time PCR (RT-PCR) 38 2.6.3 Nucleic Acid Sequence-based Amplification (NASBA) 39 2.6.4 Market Drivers and Restraints 45 184.108.40.206 Market Drivers 45 220.127.116.11 Market Restraints 45 2.6.5 Market and Technology Trends 45 18.104.22.168 Market Trends 45 2.6.5 2 Technology Trends 46 2.6.6 Strategic Recommendations 46